Journal profile · Oncology
Nature Reviews Clinical Oncology
ISSN 1759-4774 · eISSN 1759-4782 · Springer Nature · ENGLAND · Monthly · Founded 2009
Nature Reviews Clinical Oncology: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 94.53; subscription journal; review 6–12 weeks (community reports); community-reported acceptance: hard; 131 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Nature Reviews Clinical Oncology is published by Springer Nature and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations and Cancer Immunotherapy and Biomarkers, together about 27.5% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
We are interested in the best research from across the entire spectrum of clinical oncology, with our broad scope ensuring that the work we publish reaches the widest possible audience. This page gives more detail about the aims and scope of the journal. Nature Reviews Clinical Oncology is part of the Nature Reviews portfolio of journals. To learn more about Nature Reviews, check out this animation and the Nature Reviews page. You can also find a summary of the editorial input and checks here.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editorial board by country: none in mainland China; most named United Kingdom 10, Germany 3, United States 1, India 1, Italy 1 (17 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology10.6%
- Lung Cancer Treatments and MutationsMedicine8.5%
- Cancer Immunotherapy and BiomarkersMedicine8.3%
- CAR-T cell therapy researchMedicine6.3%
- Colorectal Cancer Treatments and StudiesMedicine5.6%
- Lymphoma Diagnosis and TreatmentMedicine4.6%
- Chronic Lymphocytic Leukemia ResearchMedicine4.6%
- HER2/EGFR in Cancer ResearchMedicine3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 94.53LetPub ·
- CiteScore 2026-06
- 126.6LetPub ·
- SJR 2026-06
- 28.08LetPub ·
- SNIP 2026-06
- 15.91LetPub ·
- h-index
- 127LetPub ·
- h-index
- 288OpenAlex ·
- i10-index
- 1,217OpenAlex ·
- 2-year mean citedness
- 28.77OpenAlex ·
- Self-citation rate
- 0.5%LetPub ·
- Share of gold OA articles
- 0.7%LetPub ·
Volume
- Articles per year
- 48LetPub ·
- Articles per year (publisher)
- 2,025Publisher website ·
Articles by year OpenAlex count · 3,374 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 98 | 7 | 191 |
| 2025 | 131 | 16 | 2,324 |
| 2024 | 128 | 17 | 7,755 |
| 2023 | 133 | 19 | 15,504 |
| 2022 | 124 | 32 | 15,549 |
| 2021 | 130 | 35 | 28,229 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- HardLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 2009
- ISSN
- 1759-4774
- Electronic ISSN
- 1759-4782
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Nature Reviews Clinical Oncology
What CAS zone is Nature Reviews Clinical Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Nature Reviews Clinical Oncology is in Zone 1 of Medicine, and in Zone 1 of the minor category Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Nature Reviews Clinical Oncology?
The latest impact factor listed by LetPub is 94.53; CiteScore 126.6, h-index 288.
How long does peer review take at Nature Reviews Clinical Oncology?
Authors report an average review time of 6–12 weeks; the community-reported acceptance is “Hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Nature Reviews Clinical Oncology based?
Of the 17 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United Kingdom (10), Germany (3) and United States (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Nature Reviews Clinical Oncology?
According to LetPub and DOAJ records, Nature Reviews Clinical Oncology is indexed in SCIE and Scopus.
Is Nature Reviews Clinical Oncology open access, and what is the APC?
Nature Reviews Clinical Oncology is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .